艾司西酞普兰药物经济学研究综述

艾司西酞普兰(Escitaloprara)是一种相对较新的选择性5-羟色胺再摄取抑制剂。来自国外的药物经济学研究表明,艾司西酞普兰治疗抑郁症和广泛性焦虑具有明显的经济性。研究者通过对国外已有研究文献进行分析发现,与西酞普兰(citalopram)、氟西汀(Fluoxetine)、帕罗西汀(Paroxetine)、帕罗西汀CR(Paroxetine CR)、盐酸舍曲林(Sertraline)、盐酸度洛西汀(Duloxetine)、文拉法辛(Venlafaxine)和文拉法辛XR(Venlafaxine XR)相比,艾司西酞普兰的不良事件发生率和平均治愈一例患者的成本显著较低,而临床产出显著优于其他产品。同时,艾司西酞普兰在提高患者生存质量和预防复发方面也显著优于其他产品。已有药物经济学研究的数据显示,与其他竞争者相比,艾司西酞普兰更具有成本-效果和成本-效用优势。

Escitalopram is a new highly selective serotonin reuptake inhibitor (SSRI). Analyses on the basis of available pharmacoeconomic investigations from oversea countries suggest that Escitalopram is an effective antidepressant in patients with Major Depressive Disorder (MDD) or Generalized Anxiety Disorder (GAD).Modelled pharmacoeconomic analyses found that Escitalopram,with the lowest ADR rate of the SRIs,had the lowest cost per successfully treated patient and best clinical outcomes when compared with citalopram, fluoxetine,paroxetine,paroxetine CR,sertraline,duloxetine,venlafaxine and venlafaxine XR. The difference reached statistical significance.Moreover,escitalopram treatment improves QoL of patients with GAD or MDD greatly and is more effective than placebo in the prevention of relapse.Overall,clinical and pharmacoeconomic datas prove that escitalopram has a cost- effectiveness and cost-utility advantage over comparators.